<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10644272
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-4819
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       132
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Jan
       </month>
       <day>
        18
       </day>
      </pubdate>
     </journalissue>
     <title>
      Annals of internal medicine
     </title>
     <isoabbreviation>
      Ann. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Hepatic failure in a patient taking rosiglitazone.
    </articletitle>
    <pagination>
     <medlinepgn>
      118-21
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Rosiglitazone maleate is the second approved oral hypoglycemic agent of the thiazolidinedione class. The first, troglitazone, has been associated with liver failure, occasionally resulting in liver transplantation or death. There have been no reports to date of rosiglitazone-associated elevations in the alanine aminotransferase level or hepatotoxicity.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To report the clinical characteristics of liver failure developing in a patient receiving rosiglitazone.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Case report.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      University hospital.
     </abstracttext>
     <abstracttext label="PATIENT" nlmcategory="METHODS">
      69-year-old man taking rosiglitazone, 4 mg/d.
     </abstracttext>
     <abstracttext label="INTERVENTION" nlmcategory="METHODS">
      Discontinuation of rosiglitazone therapy and treatment with lactulose, vitamin K, fresh frozen plasma, ventilatory assistance, and intensive care unit support.
     </abstracttext>
     <abstracttext label="MEASUREMENTS" nlmcategory="METHODS">
      Blood test monitoring, including toxicology screening, liver function tests, coagulation studies, serum chemistries, and complete blood counts.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      After 21 days of rosiglitazone therapy, hepatic failure developed. Other causes of hepatic failure, such as viruses and toxins, were excluded, although it is possible that congestive heart failure was also a causative factor. The patient recovered fully with supportive care.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Rosiglitazone may be associated with hepatic failure.
     </abstracttext>
    </abstract>
    <affiliation>
     Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia 19104, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Forman
      </lastname>
      <forename>
       L M
      </forename>
      <initials>
       LM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Simmons
      </lastname>
      <forename>
       D A
      </forename>
      <initials>
       DA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Diamond
      </lastname>
      <forename>
       R H
      </forename>
      <initials>
       RH
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Case Reports
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Ann Intern Med
    </medlineta>
    <nlmuniqueid>
     0372351
    </nlmuniqueid>
    <issnlinking>
     0003-4819
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hypoglycemic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazolidinediones
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      122320-73-4
     </registrynumber>
     <nameofsubstance>
      rosiglitazone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      52-53-9
     </registrynumber>
     <nameofsubstance>
      Verapamil
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      81093-37-0
     </registrynumber>
     <nameofsubstance>
      Pravastatin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2000 Oct 17;133(8):658
     </refsource>
     <pmid version="1">
      11033603
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2000 Sep 5;133(5):393-4
     </refsource>
     <pmid version="1">
      10979889
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2000 Jan 18;132(2):164
     </refsource>
     <pmid version="1">
      10644281
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Combined Modality Therapy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Coronary Disease
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Interactions
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ischemia
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Liver
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood supply
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Liver Failure
     </descriptorname>
     <qualifiername majortopicyn="Y">
      chemically induced
     </qualifiername>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monitoring, Physiologic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pravastatin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thiazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Thiazolidinediones
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Verapamil
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      1
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      9
     </month>
     <day>
      8
     </day>
     <hour>
      11
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      1
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10644272
    </articleid>
    <articleid idtype="pii">
     200001180-00005
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

